Professor Paul Glue is a finalist in this year's KiwiNet Awards. Photo: SUPPLIED
One in four New Zealanders will experience some form of anxiety or depressive disorder in their lifetime.
Of those, it's reported that at least 30% won't respond to traditional treatment therapies.
Professor Paul Glue from Otago University is a finalist in this year's KiwiNet Awards for his work in developing a drug that has been shown to help where others have failed.
With clinical trials and the approval process underway, he hopes to have the medication - a slow release form of ketamine - to market in less than three years.
Professor Glue talks to Mihingarangi about his research and not one - but two - groundbreaking discoveries.
Photo: 123rf
